56420-45-2 (表阿霉素,Epirubicin)

表阿霉素;表柔比星(表阿霉素);表比星;表柔比星;表阿霉霉;(8S,10S)-10-[(3'-氨基-2',3',6'-三脱氧-alpha-L-阿拉伯吡喃糖基)-O-]-6,8,11-三羟基-8-羟乙酰基-1-甲氧基-7,8,9,10-四氢并四苯-5,12-二酮;表柔吡星;10-[(3-氨基-2,3,6-三脱氧-Α-L-阿式-己吡喃糖基)氧]-7,8,9,10-四氢-6,8,11-三羟基-8-(羟乙酰基)-甲氧基-(8S-CIS)-并四苯-5,12-二酮;表柔比星、表阿霉素、表比星;

Epirubicin;10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8s-)oxy)-9;4’-epiadriamycin;epi-dx;imi28;5,12-Naphthacenedione, 10-(3-amino-2,3,6-trideoxy-.alpha.-L-arabino-hexopyranosyl)oxy-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-;5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-a-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)-;Epi-doxorubicin;4'-epiadriamycin;4'-Epi-DX;Adriblastin;Epiadriamycin;Farmarubicin;farmorubicin;Pidorubicin;WP 697;5,12-Naphthacenedione,10-[(3-amino-2,3,6-trideoxy-a-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-,(8S,10S)- (9CI);5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-a-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-,(8S-cis)-;4'-Epidoxorubicin;4'-epi-Adriamycin;4'-epi-Doxorubicin;Epidoxorubicin;Farmarubicine;NSC 256942;Pharmarubicin;(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxynaphthacene-5,12-dione;(8S-cis)-10-((3-Amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione;Ellence;EPIRUBICIN [WHO-DD];4' Epi Adriamycin;Pidorubicinum (Latin);AB00698552-14;EPIRUBICIN [INN];AB00698552_15;Epirubicina (INN-Spanish);DM6;Epirubicine [INN-French];Epirubicin [INN:BAN];(8S,10S)-10-{[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione;Epirubicina [Spanish];Epirubicinum [Latin];Pidorubicinum;4' Epidoxorubicin;BRD-K04548931-003-16-5;Epirubicin free base;EPIRUBICIN [VANDF];4' Epi DXR;DTXSID0022987;NCGC00263918-08;HY-13624;4-Epidoxorubicin;Epirubicinum [INN-Latin];Acid, 8;D07901;EPIRUBICIN [HSDB];3-Glycoloyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl-3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside;(8S,10S)-10-(((2R,4S,5R,6S)-4-Amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione;AB00698552-11;DM2;Q425122;Epirubicina [INN-Spanish];UNII-3Z8479ZZ5X;Epirubicine;BRN 1445813;5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-.alpha.-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)-;5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy-7,8,9,10-tetrahydro -6,8,(8S-cis)-;NSC-256942;Pidorubicina [INN-Spanish];(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside;IMI 28;(7S,9S)-7-[(2R,4S,5R,6S)-4-azanyl-6-methyl-5-oxidanyl-oxan-2-yl]oxy-4-methoxy-6,9,11-tris(oxidanyl)-9-(2-oxidanylethanoyl)-8,10-dihydro-7H-tetracene-5,12-dione;5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-;CCRIS 2261;(7S,9S)-7-[[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyl-2-oxanyl]oxy]-6,9,11-trihydroxy-9-(2-hydroxy-1-oxoethyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;AB00698552_16;Pidorubicine [INN-French];BDBM43839;4' Epiadriamycin;Pidorubicinum (INN-Latin);HSDB 6962;Pidorubicina (INN-Spanish);Epirubicine (INN-French);Farmorubicin (TN);(1S,3S)-3-GLYCOLOYL-1,2,3,4,6,11-HEXAHYDRO-3,5,12-TRIHYDROXY-10-METHOXY-6,11-DIOXO-1-NAPHTHACENYL 3-AMINO-2,3,6-TRIDEOXY-alpha-L-ARABINO-HEXOPYRANOSIDE;Epirubicina;SBI-0206890.P001;SCHEMBL8582;Pidorubicinum [INN-Latin];(7S,9R)-7-[(2S,4S,5R,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;AB00698552-13;L01DB03;NCGC00263918-04;NS00069619;Epi DX;4' Epi Doxorubicin;EPIRUBICIN [MI];Epirubicin (INN);A831042;DTXCID202987;5,12-NAPHTHACENEDIONE, 10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-ARABINO-HEXOPYRANOSYL)OXY)-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-8-(HYDROXYACETYL)-1-METHOXY-, (8S-CIS)-;Pidorubicina;DB00445;Epirubicine [French];4'-epi DX;Epirubicinum;(7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;(1S,3S)-3-GLYCOLOYL-1,2,3,4,6,11-HEXAHYDRO-3,5,12-TRIHYDROXY-10-METHOXY-6,11-DIOXO-1-NAPHTHACENYL 3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-ARABINO-HEXOPYRANOSIDE;(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside;(7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;Epirubicinum (Latin);Pidorubicine;56420-45-2;3Z8479ZZ5X;NSC256942;Ridorubicin;CHEBI:47898;CHEMBL417;5,12-Naphthacenedione,10-[(3-amino-2,3,6-trideoxy-a-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-;56420-45-2 (FREE BASE);EN300-7410311;Pidorubicine (INN-French);4'-Epi-DXR;5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-;Epirubicinum (INN-Latin);10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-(8S-cis)-5,12-naphthacenedione;NSC169534;FI-106;NSC-272332;NSC-307243;5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-;GNF-Pf-2453;Ferrate(1-),3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione]decachlorotri-, hydrogen, (8S-cis)-;SCHEMBL233853;NSC321796;FT-0630692;FT-0656147;5, 10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-, mixt. with native calf thymus DNA;Adriamycin hydrochloride (Salt/Mix);Triferric doxorubicin;DOX HCl (Salt/Mix);Adriamycin-DNA hydrochloride;7-(4-amino-5-hydroxy-6-methyloxan-2-yl)oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;NSC307242;NSC-303831;FT-0601614;Neuro_000057;NSC-307242;ADR (Salt/Mix);NSC272332;NSC-169534;NSC302662;NSC-272708;BRD-A76941896-001-01-6;NSC272707;(8S,10S)-10-[[(2R,4S,5S,6S)-4-Amino-5-hydroxy-6-methyl-2-tetrahydropyranyl]oxy]-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione;AOJJSUZBOXZQNB-UHFFFAOYSA-N;5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-;ADM;Doxorubicin hydrochloride (Salt/Mix);7-[(4-amino-5-hydroxy-6-methyl-2-oxanyl)oxy]-6,9,11-trihydroxy-9-(2-hydroxy-1-oxoethyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;Adriamycin Fe3Cl10 H;NSC307243;NSC-303830;SY224845;BRD-A76941896-003-01-2;Ferrate (1-),3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione]decachlorotri-, hydrogen, (8S-cis);NSC303830;Nucleic acid, sodium salt, compound with (8S-cis)-10-[(3-amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione hydrochloride;BRD-A76941896-003-02-0;Q27163668;3-Glycoloyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl 3-amino-2,3,6-trideoxy-L-lyxo-hexopyranoside, (1S,3S)-;3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-1-naphthacenyl 3-amino-2,3,6-trideoxyhexopyranoside;(8S,10S)-10-[(3-Amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione;NSC-302662;CHEMBL263733;NSC-321796;MFCD00869292;NSC272708;NSC-272707;Dextran,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione;Neuro_000121;CHEBI:91872;AKOS005434002;NSC267703;NSC303831;BRD-K04548931-003-13-2;NCGC00263918-06;

MFCD01713214

AOJJSUZBOXZQNB-VTZDEGQISA-N

1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22-,27-/m0/s1

O([C@H]1C[C@@H]([C@H]([C@H](C)O1)O)N)[C@@H]1C2C(=C3C(C4C(=CC=CC=4C(C3=C(C=2C[C@@](C(CO)=O)(C1)O)O)=O)OC)=O)O

None

抗肿瘤药物。

化合物(I)经三氟乙酸酐N-酰化,以对氨基进行保护,得到化合物(Ⅱ)。再氧化为酮(Ⅲ),然后还原为醇(Ⅳ)。在酸作用下去除醚键,再经三氟乙酸酐酯化为化合物(Ⅵ),然后进行选择性氯代,得到所需的侧链(VII)。 化合物(Ⅷ)经二甲缩丙酮反应成缩酮(Ⅸ),然后和上述制得的侧链(Ⅶ)反应,得到的化合物(X)水解,即得表柔比星。